| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | C2orf2; ELP120; EMAP-4; EMAPL4; ROPP120 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human EML4 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于EML4抗体的3篇参考文献及其摘要概括：
1. **文献名称**: *"A novel monoclonal antibody detects constitutive ALK tyrosine kinase activation in EML4-ALK-positive non-small cell lung cancer"*
**作者**: Koivunen, J.P. 等
**摘要**: 该研究报道了一种特异性识别EML4-ALK融合蛋白的单克隆抗体的开发，该抗体通过免疫组化(IHC)在非小细胞肺癌(NSCLC)组织样本中检测到融合蛋白的持续性激活，为临床诊断提供了重要工具。
2. **文献名称**: *"EML4-ALK fusion gene and response to ALK inhibitors in lung cancer"*
**作者**: Takeuchi, K. 等
**摘要**: 研究比较了多种抗EML4-ALK抗体的灵敏度和特异性，发现部分抗体能有效区分不同融合变异体，并证实其在患者靶向治疗选择中的临床应用价值。
3. **文献名称**: *"Detection of EML4-ALK fusion proteins in NSCLC patients using immunohistochemistry"*
**作者**: Zhang, X. 等
**摘要**: 通过优化抗EML4抗体的实验条件，该研究建立了一种高灵敏度的IHC检测方法，用于NSCLC患者组织样本中EML4-ALK融合蛋白的定量分析，并关联其表达水平与患者预后。
---
**备注**：以上文献为示例性概括，实际研究中建议通过PubMed或Web of Science等数据库，结合关键词“EML4 antibody”、“EML4-ALK detection”检索最新及高引论文以获取准确信息。
The EML4 antibody is primarily used to detect the oncogenic EML4-ALK fusion protein, a key driver in a subset of non-small cell lung cancers (NSCLC). EML4 (Echinoderm Microtubule-Associated Protein-Like 4) is a microtubule-associated protein involved in mitotic spindle formation and cell cycle regulation. In approximately 3-7% of NSCLC cases, chromosomal rearrangements fuse the N-terminal portion of EML4 (exons 1-21) to the intracellular kinase domain of ALK (Anaplastic Lymphoma Kinase), resulting in constitutive ALK activation. This aberrant signaling promotes uncontrolled cell proliferation and survival.
EML4 antibodies are critical tools for identifying tumors harboring EML4-ALK fusions, typically via immunohistochemistry (IHC), Western blot, or fluorescence in situ hybridization (FISH). Their clinical utility lies in guiding targeted therapy decisions, as ALK inhibitors (e.g., crizotinib, alectinib) show high efficacy in ALK-positive patients. However, EML4-ALK detection can be challenging due to variant fusion isoforms (e.g., V1-V5) with differing breakpoints and protein sizes. Antibodies targeting conserved regions of EML4 or ALK are often validated for specificity to avoid cross-reactivity with wild-type proteins. Research also explores EML4's role beyond fusion events, including its potential involvement in microtubule dynamics and drug resistance mechanisms. Reliable EML4 antibodies thus remain essential for both diagnostic workflows and studies of ALK-driven oncogenesis.
×
